Research progress in relationship between protein phosphatase 2A and occurrence and development of tumor
10.13481/j.1671-587X.20250229
- VernacularTitle:蛋白磷酸酶2A与肿瘤发生发展关系的研究进展
- Author:
Huiling ZHANG
1
;
Wenxiu GUO
;
Jun MENG
Author Information
1. 内蒙古医科大学附属医院检验科,内蒙古 呼和浩特 010050
- Keywords:
Protein phosphatase 2A;
Endogenous inhibitor;
Tumor;
Cancerous inhibitor of protein phosphatase 2A;
Protein phosphatase methylesterase-1
- From:
Journal of Jilin University(Medicine Edition)
2025;51(2):534-540
- CountryChina
- Language:Chinese
-
Abstract:
Protein phosphatase 2A(PP2A)is one of the major serine-threonine protein phosphatases in mammalian cells which plays an important role in regulating biological activities such as cellular mitosis and protein dephosphorylation.PP2A acts as a tumor suppressor and has been demonstrated to be genetically altered or functionally inactivated in a variety of solid cancers and leukemias,and its activity is inhibited,leading to subsequent proliferation of tumor cells.Clinical studies have shown that endogenous inhibitors such as SET,cancerous inhibitor of PP2A(CIP2A)and protein phosphatase methylesterase-1(PME-1)may reduce PP2A activity,which could be important indicators of tumor progression or recurrence.On the other hand,PP2A-activating drugs(e.g.FTY720)can restore the tumor-suppressing activity of PP2A by altering the structure of the inhibitor SET,thus effectively inhibiting tumor development.Therefore,PP2A and its inhibitors may serve as potential therapeutic targets in clinic.This article provides a comprehensive review on the mechanism of action of PP2A and its inhibitors in the pathogenesis of malignant tumor as well as their applications in oncotherapy,aiming to provide new directions for the treatment of malignant tumors.
